A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
In brief
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
Key facts
- Study ID
- NCT05864144
- Run by
- Sensei Biotherapeutics, Inc.
- People needed
- 98
- Starts
- 2023-05-31
- Expected to finish
- 2027-06-01
- Last updated by the study team
- 2025-08-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCLA Hematology/Oncology — Los Angeles, California, United States
- University of Colorado Cancer Center - Anschutz Medical — Aurora, Colorado, United States
- Norton Healthcare — Louisville, Kentucky, United States
- Henry Ford Cancer — Detroit, Michigan, United States
- Icahn School of Medicine at Mt. Sinai — New York, New York, United States
- University of Pennsylvania, Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania, United States
- Sanford Cancer Center — Sioux Falls, South Dakota, United States
- NEXT Oncology Dallas — Irving, Texas, United States
- South Texas Accelerated Research Therapeutics (START) San Antonio — San Antonio, Texas, United States
- START Mountain Region — West Valley City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.